Lumen Bioscience has published data demonstrating a needle-free, spirulina-produced recombinant vaccine that protects against malaria.
The research, conducted in collaboration with the University of Washington, was published in the peer-reviewed journal, Nature Partner Journals (NPJ) Vaccines.
Lumen Bioscience pioneered genetic engineering methods to highly express bioactive proteins in spirulina. The published research details how this platform was used to express a malaria protein antigen that can be delivered intranasally and later boosted with a simple oral booster.
The low cost and scalability of Lumen Bioscience’s production platform, coupled with easy, needle-free administration, could greatly expand real-world access to malaria vaccines, the company said.
